Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

Amgen stock slouched Wednesday after an Eli Lilly executive called the company's early-stage test results for a weight-loss drug "a bit underwhelming." Please watch the video at Investors.com ...

MariTide (maridebart cafraglutide; formerly AMG 133) hit the headlines in May after Amgen management expressed its excitement about the GLP-1 and GIP-directed bispecific antibody in its first ...

The latest trading session saw Amgen (AMGN) ending at $267.10, denoting a -1.14% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.12% for the ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Since my previous article, shares of Amgen meaningfully lagged the S&P 500 index. The company's revenue and non-GAAP EPS climbed higher in the third quarter. Amgen's deleveraging efforts are ...

Thousand Oaks, California-based Amgen Inc. (AMGN) discovers, develops, and manufactures innovative medicines aimed at improving the lives of millions. With a market cap of $142 billion ...